The prevalence rate of degenerative knee arthritis in the Chinese population is about 15%, and 3.5 million people suffer from joint pain. Osteoarthritis is the number one enemy of motor dysfunction in the elderly. National Chung Hsing University, Asia University Affiliated Hospital, Changhua Xiuchuan Hospital and Taichung Tzu Chi Hospital cooperate to use autologous blood to differentiate into anti-inflammatory M2 macrophages, which can produce type II collagen protein, which is expected to become a new generation of therapy. The progress of degenerative arthritis was reversed, and the experimental results were published in the top international journal “Scientific Reports”.
The latest research by Professor Su Honglin from the Department of Life Sciences of Chung Hsing University and Professor Lin Zhilong, Vice President of Asia University Affiliated Hospital, using special culture conditions, can promote the differentiation of blood monocytes into anti-inflammatory M2 macrophages, and the differentiated cells can produce type II collagen protein. Transplantation of these cells into arthritic animals can effectively and long-term suppress the inflammatory response. The research results will be published in the internationally renowned journal “Scientific Reports” in December 2022.
Lin Zhilong said that osteoarthritis is often accompanied by cartilage wear and inflammation of surrounding tissues, causing long-term pain and formation of bone spurs. At present, there is no medical solution that can reverse degenerative arthritis, so that the elderly who are currently suffering from this disease will eventually have to replace their artificial joints. If you suffer from severe degenerative arthritis and you don’t want to have surgery or you can’t have surgery, you can only take painkillers for a long time to maintain your quality of life. Therefore, with this revolutionary discovery, in the future, blood mononuclear spheres can be isolated and cultured in vitro, and injected into the joint cavity to supplement type II collagen in the future.
Professor Li Peiyuan, the honorary president of Xiuchuan Medical System and a famous orthopedic doctor, said that at present, it does not need to be cultured, and using concentrated blood mononuclear cells to relieve arthritis symptoms is also a novel solution that meets clinical needs. can be treated.
It was found that a single dose of concentrated mononuclear cells can improve the patient’s pain control and motor function for two years, and the curative effect exceeds expectations. The outstanding results have also been accepted by internationally renowned journals and will be published in the near future. Based on the results of the preliminary trials, the team will expand the number of cases in the future, design more rigorous clinical trials and combine image analysis to provide more complete clinical data to support the efficacy of PCP for degenerative arthritis and enter the international market.
Xue Fusheng, president of National Chung Hsing University, said that Chung Hsing University, through the promotion of doctoral programs in translational medicine, medical biotechnology, and biotechnology industry in the School of Biological Sciences, integrates the advantages of academics, medical care, and industry, so that doctors and professors can implement human body Clinical trials, jointly develop clinical treatments that meet the needs of patients, and create a win-win platform for production, learning, and research. (Video: https://youtu.be/9dOQmbfTaLY)